Zenke Y, Niho S, Toi Y, Yamaguchi M, et al. Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study. Lung Cancer 2025;206:108633.
PMID: 40602204